|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics for hispanics/latinos, 2012. CA Cancer J Clin.
62:283–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kong Q and Qiu M: Long noncoding RNA
SNHG15 promotes human breast cancer proliferation, migration and
invasion by sponging miR-211-3p. Biochem Biophys Res Commun.
495:1594–1600. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luo Q, Wei C, Li X, Li J, Chen L, Huang Y,
Song H, Li D and Fang L: MicroRNA-195-5p is a potential diagnostic
and therapeutic target for breast cancer. Oncol Rep. 31:1096–1102.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Greaney ML, Sprunck-Harrild K, Ruddy KJ,
Ligibel J, Barry WT, Baker E, Meyer M, Emmons KM and Partridge AH:
Study protocol for young & strong: A cluster randomized design
to increase attention to unique issues faced by young women with
newly diagnosed breast cancer. BMC Public Health. 15:372015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: Past, present, and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wiemer EA: The role of microRNAs in
cancer: No small matter. Eur J Cancer. 43:1529–1544. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iorio MV and Croce CM: MicroRNAs in
cancer: small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ke M, Zhang Z, Cong L, Zhao S, Li Y, Wang
X, Lv Y, Zhu Y and Dong J: MicroRNA-148b-colony-stimulating
factor-1 signaling-induced tumor-associated macrophage infiltration
promotes hepatocellular carcinoma metastasis. Biomed Pharmacother.
120:1095232019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han L, Cui D, Li B, Xu WW, Lam AKY, Chan
KT, Zhu Y, Lee NPY, Law SYK, Guan XY, et al: MicroRNA-338-5p
reverses chemoresistance and inhibits invasion of esophageal
squamous cell carcinoma cells by targeting Id-1. Cancer Sci.
110:3677–3688. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shang S, Wang J, Chen S, Tian R, Zeng H,
Wang L, Xia M, Zhu H and Zuo C: Exosomal miRNA-1231 derived from
bone marrow mesenchymal stem cells inhibits the activity of
pancreatic cancer. Cancer Med. 8:7728–7740. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eberlein A, Takasuga A, Setoguchi K, Pfuhl
R, Flisikowski K, Fries R, Klopp N, Fürbass R, Weikard R and Kühn
C: Dissection of genetic factors modulating fetal growth in cattle
indicates a substantial role of the non-SMC condensin I complex,
subunit G (NCAPG) gene. Genetics. 183:951–964. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu M and Thomas PD: GO functional
similarity clustering depends on similarity measure, clustering
method, and annotation completeness. BMC Bioinformatics.
20:1552019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li S, Xuan Y, Gao B, Sun X, Miao S, Lu T,
Wang Y and Jiao W: Identification of an eight-gene prognostic
signature for lung adenocarcinoma. Cancer Manag Res. 10:3383–3392.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Arai T, Okato A, Yamada Y, Sugawara S,
Kurozumi A, Kojima S, Yamazaki K, Naya Y, Ichikawa T and Seki N:
Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits
cancer cell aggressiveness and is involved in CRPC. Cancer Med.
7:1988–2002. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liang ML, Hsieh TH, Ng KH, Tsai YN, Tsai
CF, Chao ME, Liu DJ, Chu SS, Chen W, Liu YR, et al: Downregulation
of miR-137 and miR-6500-3p promotes cell proliferation in pediatric
high-grade gliomas. Oncotarget. 7:19723–19737. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goto Y, Kurozumi A, Arai T, Nohata N,
Kojima S, Okato A, Kato M, Yamazaki K, Ishida Y, Naya Y, et al:
Impact of novel miR-145-3p regulatory networks on survival in
patients with castration-resistant prostate cancer. Br J Cancer.
117:409–420. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Gao B, Tan PY, Handoko YA, Sekar
K, Deivasigamani A, Seshachalam VP, OuYang HY, Shi M, Xie C, et al:
Genome-wide CRISPR knockout screens identify NCAPG as an essential
oncogene for hepatocellular carcinoma tumor growth. FASEB J.
33:8759–8770. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang L, Ren L, Chen H, Pan J, Zhang Z,
Kuang X, Chen X, Bao W, Lin C, Zhou Z, et al: NCAPG confers
trastuzumab resistance via activating SRC/STAT3 signaling pathway
in HER2-positive breast cancer. Cell Death Dis. 11:5472020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pontén F, Schwenk JM, Asplund A and
Edqvist PH: The human protein atlas as a proteomic resource for
biomarker discovery. J Intern Med. 270:428–446. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jézéquel P, Campone M, Gouraud W,
Guérin-Charbonnel C, Leux C, Ricolleau G and Campion L:
bc-GenExMiner: An easy-to-use online platform for gene prognostic
analyses in breast cancer. Breast Cancer Res Treat. 131:765–775.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jézéquel P, Frénel JS, Campion L,
Guérin-Charbonnel C, Gouraud W, Ricolleau G and Campone M:
bc-GenExMiner 3.0: New mining module computes breast cancer gene
expression correlation analyses. Database (Oxford).
2013:bas0602013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mizuno H, Kitada K, Nakai K and Sarai A:
PrognoScan: A new database for meta-analysis of the prognostic
value of genes. BMC Med Genomics. 2:182009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li Y, Zou L, Li Q, Haibe-Kains B, Tian R,
Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, et al:
Amplification of LAPTM4B and YWHAZ contributes to chemotherapy
resistance and recurrence of breast cancer. Nat Med. 16:214–218.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bos PD, Zhang XH, Nadal C, Shu W, Gomis
RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA and
Massagué J: Genes that mediate breast cancer metastasis to the
brain. Nature. 459:1005–1009. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Loi S, Haibe-Kains B, Desmedt C, Lallemand
F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, et
al: Definition of clinically distinct molecular subtypes in
estrogen receptor-positive breast carcinomas through genomic grade.
J Clin Oncol. 25:1239–1246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sotiriou C, Wirapati P, Loi S, Harris A,
Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al:
Gene expression profiling in breast cancer: Understanding the
molecular basis of histologic grade to improve prognosis. J Natl
Cancer Inst. 98:262–272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Y, Sieuwerts AM, McGreevy M, Casey
G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, et
al: The 76-gene signature defines high-risk patients that benefit
from adjuvant tamoxifen therapy. Breast Cancer Res Treat.
116:303–309. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schmidt M, Böhm D, von Törne C, Steiner E,
Puhl A, Pilch H, Lehr HA, Hengstler JG, Kölbl H and Gehrmann M: The
humoral immune system has a key prognostic impact in node-negative
breast cancer. Cancer Res. 68:5405–5413. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Loi S, Haibe-Kains B, Desmedt C, Wirapati
P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, et
al: Predicting prognosis using molecular profiling in estrogen
receptor-positive breast cancer treated with tamoxifen. BMC
Genomics. 9:2392008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma XJ, Wang Z, Ryan PD, Isakoff SJ,
Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT,
et al: A two-gene expression ratio predicts clinical outcome in
breast cancer patients treated with tamoxifen. Cancer Cell.
5:607–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM,
Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu
J, et al: Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet. 365:671–679.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hall P, Ploner A, Bjöhle J, Huang F, Lin
CY, Liu ET, Miller LD, Nordgren H, Pawitan Y, Shaw P, et al:
Hormone-replacement therapy influences gene expression profiles and
is associated with breast-cancer prognosis: A cohort study. BMC
Med. 4:162006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou Y, Yau C, Gray JW, Chew K, Dairkee
SH, Moore DH, Eppenberger U, Eppenberger-Castori S and Benz CC:
Enhanced NF kappa B and AP-1 transcriptional activity associated
with antiestrogen resistant breast cancer. BMC Cancer. 7:592007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chin K, DeVries S, Fridlyand J, Spellman
PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et
al: Genomic and transcriptional aberrations linked to breast cancer
pathophysiologies. Cancer Cell. 10:529–541. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Miller LD, Smeds J, George J, Vega VB,
Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET and Bergh
J: An expression signature for p53 status in human breast cancer
predicts mutation status, transcriptional effects, and patient
survival. Proc Natl Acad Sci USA. 102:13550–13555. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ivshina AV, George J, Senko O, Mow B,
Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, et al:
Genetic reclassification of histologic grade delineates new
clinical subtypes of breast cancer. Cancer Res. 66:10292–10301.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Desmedt C, Piette F, Loi S, Wang Y,
Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y,
d'Assignies MS, et al: Strong time dependence of the 76-gene
prognostic signature for node-negative breast cancer patients in
the TRANSBIG multicenter independent validation series. Clin Cancer
Res. 13:3207–3214. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42((Database Issue)): D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wong NW, Chen Y, Chen S and Wang X:
OncomiR: An online resource for exploring pan-cancer microRNA
dysregulation. Bioinformatics. 34:713–715. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45((W1)):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fernandez-Martinez A, Krop IE, Hillman DW,
Polley MY, Parker JS, Huebner L, Hoadley KA, Shepherd J, Tolaney S,
Henry NL, et al: Survival, pathologic response, and genomics in
CALGB 40601 (alliance), a neoadjuvant phase III trial of
paclitaxel-trastuzumab with or without lapatinib in HER2-positive
breast cancer. J Clin Oncol. 38:4184–4193. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Elsharawy KA, Mohammed OJ, Aleskandarany
MA, Hyder A, El-Gammal HL, Abou-Dobara MI, Green AR, Dalton LW and
Rakha EA: The nucleolar-related protein Dyskerin pseudouridine
synthase 1 (DKC1) predicts poor prognosis in breast cancer. Br J
Cancer. 123:1543–1552. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kuba MG, Lester SC, Bowman T, Stokes SM,
Taneja KL, Garber JE and Dillon DA: Histopathologic features of
breast cancer in Li-Fraumeni syndrome. Mod Pathol. Jul
7–2020.(Online ahead of print).
|
|
53
|
Lou W, Chen J, Ding B, Chen D, Zheng H,
Jiang D, Xu L, Bao C, Cao G and Fan W: Identification of
invasion-metastasis-associated microRNAs in hepatocellular
carcinoma based on bioinformatic analysis and experimental
validation. J Transl Med. 16:2662018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lou W, Liu J, Ding B, Xu L and Fan W:
Identification of chemoresistance-associated miRNAs in breast
cancer. Cancer Manag Res. 10:4747–4757. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lou W, Liu J, Gao Y, Zhong G, Ding B, Xu L
and Fan W: MicroRNA regulation of liver cancer stem cells. Am J
Cancer Res. 8:1126–1141. 2018.PubMed/NCBI
|
|
56
|
Liao WL, Lin JY, Shieh JC, Yeh HF, Hsieh
YH, Cheng YC, Lee HJ, Shen CY and Cheng CW: Induction of G2/M phase
arrest by diosgenin via activation of Chk1 kinase and Cdc25C
regulatory pathways to promote apoptosis in human breast cancer
cells. Int J Mol Sci. 21:1722019. View Article : Google Scholar
|
|
57
|
Pan Z, Zhang X, Yu P, Chen X, Lu P, Li M,
Liu X, Li Z, Wei F, Wang K, et al: Cinobufagin induces cell cycle
arrest at the G2/M phase and promotes apoptosis in malignant
melanoma cells. Front Oncol. 9:8532019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang Q, Su R, Shan C, Gao C and Wu P:
Non-SMC condensin I complex, subunit G (NCAPG) is a novel mitotic
gene required for hepatocellular cancer cell proliferation and
migration. Oncol Res. 26:269–276. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ai J, Gong C, Wu J, Gao J, Liu W, Liao W
and Wu L: MicroRNA-181c suppresses growth and metastasis of
hepatocellular carcinoma by modulating NCAPG. Cancer Manag Res.
11:3455–3467. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bertoli G, Cava C and Castiglioni I: The
potential of miRNAs for diagnosis, treatment and monitoring of
breast cancer. Scand J Clin Lab Invest Suppl. 245:S34–S39. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhang X, Gao D, Fang K, Guo Z and Li L:
Med19 is targeted by miR-101-3p/miR-422a and promotes breast cancer
progression by regulating the EGFR/MEK/ERK signaling pathway.
Cancer Lett. 444:105–115. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wang H, Wang L, Tang L, Luo J, Ji H, Zhang
W, Zhou J, Li Q and Miao L: Long noncoding RNA SNHG6 promotes
proliferation and angiogenesis of cholangiocarcinoma cells through
sponging miR-101-3p and activation of E2F8. J Cancer. 11:3002–3012.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yang R, Xing L, Zheng X, Sun Y, Wang X and
Chen J: The circRNA circAGFG1 acts as a sponge of miR-195-5p to
promote triple-negative breast cancer progression through
regulating CCNE1 expression. Mol Cancer. 18:42019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Han LC, Wang H, Niu FL, Yan JY and Cai HF:
Effect miR-214-3p on proliferation and apoptosis of breast cancer
cells by targeting survivin protein. Eur Rev Med Pharmacol Sci.
23:7469–7474. 2019.PubMed/NCBI
|
|
65
|
Flores-Pérez A, Marchat LA,
Rodríguez-Cuevas S, Bautista VP, Fuentes-Mera L, Romero-Zamora D,
Maciel-Dominguez A, de la Cruz OH, Fonseca-Sánchez M, Ruíz-García
E, et al: Suppression of cell migration is promoted by miR-944
through targeting of SIAH1 and PTP4A1 in breast cancer cells. BMC
Cancer. 16:3792016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gao J, Xia R, Chen J, Gao J, Luo X, Ke C,
Ren C, Li J and Mi Y: Inhibition of esophageal-carcinoma cell
proliferation by genistein via suppression of JAK1/2-STAT3 and
AKT/MDM2/p53 signaling pathways. Aging (Albany NY). 12:6240–6259.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Jiang W, Hou L, Wei J, Du Y, Zhao Y, Deng
X and Lin X: Hsa-miR-217 inhibits the proliferation, migration, and
invasion in non-small cell lung cancer cells via targeting SIRT1
and P53/KAI1 signaling. Balkan Med J. 37:208–214. 2020.PubMed/NCBI
|
|
68
|
Zheng X, Zhang J, Fang T, Wang X, Wang S,
Ma Z, Xu Y, Han C, Sun M, Xu L, et al: The long non-coding RNA
PIK3CD-AS2 promotes lung adenocarcinoma progression via
YBX1-mediated suppression of p53 pathway. Oncogenesis. 9:342020.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Liu K, Li Y, Yu B, Wang F, Mi T and Zhao
Y: Silencing non-SMC chromosome-associated polypeptide G inhibits
proliferation and induces apoptosis in hepatocellular carcinoma
cells. Can J Physiol Pharmacol. 96:1246–1254. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Liu ZK, Zhang RY, Yong YL, Zhang ZY, Li C,
Chen ZN and Bian H: Identification of crucial genes based on
expression profiles of hepatocellular carcinomas by bioinformatics
analysis. PeerJ. 7:e74362019. View Article : Google Scholar : PubMed/NCBI
|
